In the recent years, integrase (IN) has emerged as an important new target
for the development of anti-HIV-1 agents. The enzyme is involved in a key stage of the
retroviral replicative cycle, and interacts with a range of cellular co-factors. Due to the
absolute necessity of the enzyme for successful infection and the range of cellular cofactors
employed by the enzyme, new ways of targeting both IN and its cofactors could
yield agents with improved resistance profiles. Allosteric inhibitors are currently
receiving a great deal of focus from both academia and industry alike and offer the
possibility of a new class of anti-HIV-1 inhibitor.
Keywords: ALLINI, Allosteric, HIV-1, Integrase, LEDGIN, LEDGF/p75,
Multimerization, PIC, Retrovirus, STI.
